Exact Sciences Corporation
EXAS
Xếp hạng trong cổ phiếu
#1130
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Giá cổ phiếu
$104.91
Đồng bộ lần cuối: 2026-03-23
Vốn hóa thị trường
$20.03B
Thay đổi (1 ngày)
0.00%
Thay đổi (1 năm)
66.76%
Quốc gia
US
Giao dịch Exact Sciences Corporation (EXAS)
Danh mục
Healthcare
Lịch sử giá cổ phiếu của Exact Sciences Corporation (EXAS)
Giá đóng cửa cao nhất: $103.73 vào 2026-03-01
Giá đóng cửa thấp nhất: $12.01 vào 2001-02-01
Giá đóng cửa thấp nhất: $12.01 vào 2001-02-01
Lịch sử giá cổ phiếu của Exact Sciences Corporation từ 2001 đến 2026
Hiệu suất giá cổ phiếu hàng năm
| Năm | Hiệu suất |
|---|---|
| 2026 (TTM) | -6.08% |
| 2025 | 69.09% |
| 2024 | -12.49% |
| 2023 | 42.90% |
| 2022 | -39.16% |
| 2021 | -40.80% |
| 2020 | 48.89% |
| 2019 | 34.19% |
| 2018 | 25.30% |
| 2017 | 281.21% |
| 2016 | 57.59% |
| 2015 | -67.41% |
| 2014 | 124.59% |
| 2013 | 17.94% |
| 2012 | 26.41% |
| 2011 | 36.65% |
| 2010 | 107.64% |
| 2009 | 526.88% |
| 2008 | -86.19% |
| 2007 | 44.84% |
| 2006 | 26.38% |
| 2005 | -51.35% |
| 2004 | -60.90% |
| 2003 | -11.30% |
| 2002 | 12.77% |
| 2001 | 0.00% |
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
| Công ty | Giá cổ phiếu | Thay đổi 1năm% | Quốc gia |
|---|---|---|---|
| $694.53 | 22.45% |
US
|
|
| $234.00 | 7.29% |
US
|
|
| $416.01 | 121.26% |
US
|
|
| $21.16 | 49.45% |
CN
|
|
| $177.93 | 21.98% |
US
|
